24/7 Market News Snapshot 23 October, 2025 – N2OFF, Inc. Common Stock (NASDAQ:NITO)

October 23, 2025

DENVER, Colo., 23 October, 2025 (www.247marketnews.com) – (NASDAQ:NITO) are discussed in this article.
N2OFF, Inc. (NASDAQ:NITO) has experienced a noteworthy surge in its stock performance, having opened today at $3.93 and currently trading at $4.401, reflecting a remarkable increase of 14.91%. Following the previous session close at $3.83, this upward momentum signifies strong bullish sentiment in the market. The trading volume stands at 4.48 million shares, indicating heightened investor interest and a potential for increased price volatility. Traders are advised to closely monitor moving averages and volume trends, as sustained strength may hinge on the stock’s ability to maintain its position above crucial support levels.

Further reinforcing its market presence, N2OFF has successfully completed the acquisition of MitoCareX Bio Ltd., the majority-owned subsidiary of SciSparc Ltd. This strategic acquisition, finalized on October 20, 2025, is in line with N2OFF’s mission to advance innovative therapies targeting difficult-to-treat cancers, particularly through the exploration of mitochondrial SLC25 protein families.

MitoCareX is focused on developing cutting-edge anti-cancer therapeutics, utilizing its proprietary MITOLINE™ technology. This technology integrates advanced algorithmic modeling for 3D comparative protein analysis with high-throughput in-vitro screening, creating a strong foundation for validating the anti-cancer effects of small molecules. The global cancer therapeutics market is expected to grow significantly, from approximately $211.02 billion in 2025 to $378.62 billion by 2032, positioning N2OFF advantageously to seize emerging opportunities within oncology.

The acquisition entails N2OFF purchasing 6,622 shares of MitoCareX for $700,000 and facilitating the exchange of additional shares from former shareholders, who will obtain a 40% stake in N2OFF’s fully diluted capital stock, alongside milestone-based stock issuances. This strategic governance shift will see appointees from N2OFF directing MitoCareX, with Chairman Amitay Weiss playing a vital role in propelling MitoCareX toward its ambitious objectives. Overall, this acquisition signifies a pivotal moment for N2OFF, reflecting its commitment to pioneering advancements in cancer treatment and enhancing its trajectory in the biopharmaceutical sector.

Related news for (NITO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.